*Bonfiglio F, Bruscaggin A, Guidetti F et al. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood. 2022; 139(5):732-747. doi: 10.1182/blood.2021012386

*Iseas S, Sendoya JM, Robbio J, et al. Prognostic Impact of An Integrative Landscape of Clinical, Immune, and Molecular Features in Non-Metastatic Rectal Cancer. Front Oncol. 2022 Jan 7;11:801880. doi: 10.3389/fonc.2021.801880

*Nuan-Aliman S, Bordereaux D, Thieblemont C, Baud V. The Alternative RelB NF-kB Subunit Exerts a Critical Survival Function upon Metabolic Stress in Diffuse Large B-Cell Lymphoma-Derived Cells.  Biomedicines. 2022;10(2):348. doi: 10.3390/biomedicines10020348

*Takenaka IKTM, Bartelli TF, Defelicibus A, et al. Exome and Tissue-Associated Microbiota as Predictive Markers of Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer. Front Oncol. 2022; 12: 809441. doi: 10.3389/fonc.2022.809441


*Aschero R, Francis JH, Ganiewich d, et al. Recurrent Somatic Chromosomal Abnormalities in Relapsed Extraocular Retinoblastoma. Cancers (Basel). 2021;13(4):673. doi: 10.3390/cancers13040673

*Bolis M, Bossi D, Vallerga A, et al. Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nat Commun. 2021; 12: 7033. doi: 10.1038/s41467-021-26840-5

*Cancela MB, Zugbi S, Winter U, et al. A decision process for drug discovery in retinoblastoma. Invest New Drugs. 2021;39(2):426-441. doi: 10.1007/s10637-020-01030-0

*Formaggio N, Rubin MA, Theurillat JP, et al. Loss and revival of androgen receptor signaling in advanced prostate cancer. Oncogene. 2021;40(7):1205-1216. doi: 10.1038/s41388-020-01598-0.

*Golubicki M, Díaz-Gay M, Bonjoch L, et al. Comprehensive Genomic Characterization of Fifteen Early-Onset Lynch-Like Syndrome Colorectal Cancers. Cancers (Basel). 2021; 12;13(6):1259. doi: 10.3390/cancers13061259

*Iseas S, Golubicki M, Robbio J, et al. A clinical and molecular portrait of non-metastatic anal squamous cell carcinoma. Transl Oncol. 2021;14(6):101084. doi: 10.1016/j.tranon.2021.101084

*Liu J, Ottaviani D, Sefta M, et al. A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression  Nat Commun. 2021; 12(1):5578. doi: 10.1038/s41467-021-25792-0

*Moia R, Favini C, Ferri V, et al. Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma. Br J Haematol. 2021;195(1):108-112. doi: 10.1111/bjh.17718

*Winter U, Ganiewich D, Ottaviani D, et al. Genomic and Transcriptomic Tumor Heterogeneity in Bilateral Retinoblastoma. JAMA Ophthalmol. 2021;138(5):569-574. doi: 10.1001/jamaophthalmol.2020.0427


*Condoluci A, Terzi di Bergamo L, Langerbeins P, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020;135(21):1859-1869. doi: 10.1182/blood.2019003453

*Evrard D, Hourseau M, Couvelard A, et al. PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma. Oncoimmunology. 2020;9(1):1844403. doi: 10.1080/2162402X.2020.1844403.

*Glembotsky AC, Marin Oyarzún CP, De Luca G, et al . First description of revertant mosaicism in familial platelet disorder with predisposition to acute myelogenous leukemia: correlation with the clinical phenotype. Haematologica. 2020;105(10):e535.  doi: 10.3324/haematol.2020.253070

*Golubicki M, Bonjoch L,Acuña-Ochoa JG, et al. Germline biallelic Mcm8 variants are associated with early-onset Lynch-like syndrome. JCI Insight. 2020; 17;5(18):e140698. doi: 10.1172/jci.insight.140698

*Recondo G, Mahjoubi L, Maillard A, et al. Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. NPJ Precis Oncol. 2020;4:27. doi: 10.1038/s41698-020-00130-7.

*Sendoya JM, Iseas S, Coraglio M et al. Pre-Existing Tumoral B Cell Infiltration and Impaired Genome Maintenance Correlate with Response to Chemoradiotherapy in Locally Advanced Rectal Cancer. Cancers (Basel). 2020; 12(8): 2227. doi: 10.3390/cancers12082227

*Tam C, Seymour JF. A predictive tool for early-stage CLL. Blood. 2020;135(21):1820-1821. doi: 10.1182/blood.2020005426

*Zugbi S, Ganiewich D, Bhattacharyya A, et al. Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma. Cancers (Basel). 2020;22;12(9):2714. doi: 10.3390/cancers12092714.


*Antelo M, Golubicki M, Roca E, et al. Lynch-like syndrome is as frequent as Lynch syndrome in early-onset nonfamilial nonpolyposis colorectal cancer. Int J Cancer. 2019; 145(3):705-713. doi: 10.1002/ijc.32160

*Bellini A, Bessoltane-Bentahar N, Bhalshankar J, et al. Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma. Int J Cancer. 2019. doi: 10.1002/ijc.32361

*Evrard D, Szturz P, Tijeras-Raballand A, et al. Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy. Oral Oncol. 2019; 88:29-38. doi: 10.1016/j.oraloncology.2018.10.040

*Glembotsky AC, Sliwa D, Bluteau D, et al. Downregulation of TREM-like transcript-1 and collagen receptor α2 subunit, two novel RUNX1-targets, contributes to platelet dysfunction in familial platelet disorder with predisposition to acute myelogenous leukemia. Haematologica 2019;104(6):1244-1255. doi: 10.3324/haematol.2018.188904

*Jiménez I, Chicard M, Colmet-Daage L, et al. Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosis. Int J Cancer 2019; 144(1):68-79. doi: 10.1002/ijc.31620

*Krisko A, Radman M. Protein damage, ageing and age-related diseases. Open Biol. 2019; 9(3):180249. doi: 10.1098/rsob.180249

*Nicolle R, Raffenne J, Paradis V, et al. Prognostic Biomarkers in Pancreatic Cancer: Avoiding Errata When Using the TCGA Dataset. Cancers (Basel). 2019; 11(1). pii: E126. doi: 10.3390/cancers11010126

*Radman M.  Cellular parabiosis and the latency of age-related diseases. Open Biol 2019; 9(3):180250. doi: 10.1098/rsob.180250

*Winter U, Aschero R, Fuentes F, et al. Tridimensional Retinoblastoma Cultures as Vitreous Seeds Models for Live-Cell Imaging of Chemotherapy Penetration. Int J Mol Sci. 2019;20(5). doi: 10.3390/ijms20051077


*Chicard M, Colmet-Daage L, Clement N et al. Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma. Clin Cancer Res 2018;24(4):939-949. doi: 10.1158/1078-0432.CCR-17-1586

*Cros J, Raffenne J, Couvelard A, et al. Tumor Heterogeneity in Pancreatic Adenocarcinoma. Pathobiology. 2018; 85(1-2):64-71. doi: 10.1159/000477773

*Depuydt P, Boeva V, Hocking TD, et al. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. J Natl Cancer Inst 2018;110(10):1084-1093. doi: 10.1093/jnci/djy022

*Deveau P, Colmet Daage L, Oldridge D, et al. QuantumClone: clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction. Bioinformatics 2018;34(11):1808-1816. doi: 10.1093/bioinformatics/bty016

*Raffenne J, Cros J. Molecular characterisation defines several subtypes of pancreatic ductal adenocarcinoma. [Article in French]. Bull Cancer 2018; 105(1):55-62. doi: 10.1016/j.bulcan.2017.11.010*

*Recondo G, Facchinetti F, Olaussen KA, et al. Making the first move in EGFR-driven or ALK-

* Tarantelli C, Bernasconi E, Gaudio E, et al. BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance. ESMO Open. 2018 Sep 26;3(6):e000387. doi: 10.1136/esmoopen-2018-000387 


*Perić M, Lovrić A, Šarić A. TORC1-mediated sensing of chaperone activity alters glucose metabolism and extends lifespan. Aging Cell 2017;16(5):994-1005. doi: 10.1111/acel.12623

*Roséus J, Mourah S, Ramstein G, et al. VEGF121, is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers. Oncotarget. 2017; 8(53):90808-90824. doi: 10.18632/oncotarget.19385

*Thieblemont C. Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma. Hematology Am Soc Hematol Educ Program. 2017; 2017(1): 371–378. doi: 10.1182/asheducation-2017.1.371


*Bernard S, Goldwirt L, Amorim S, et al. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. Blood 2015; 126(14): 1695–1698. doi: 10.1182/blood-2015-05-647834

*Broséus J, Chen G, Hergalant S, et al. Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses. Oncotarget 2016; 7(51): 83987–84002. doi: 10.18632/oncotarget.9793

*Chicard M, Boyault S, Colmet Daage L et al. Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma. Clin Cancer Res 2016; 22(22):5564-5573. doi: 10.1158/1078-0432.CCR-16-0500

*Cros J, Hentic O, Rebours V, et al. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. Endocr Relat Cancer 2016; 23(8):625-33. doi: 10.1530/ERC-16-0117

*Cros J, Moati E, Raffenne J, et al. Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors. Neuroendocrinology 2016; 103(5):495-9. doi: 10.1159/000440724

*Elizalde PV, Cordo Russo RI, Chervo MF et al. ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. Endocr Relat Cancer 2016;23(12):T243-T257. doi: org/10.1530/ERC-16-0360

*Fleury I, Chevret S, Pfreundschuh M, et al. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Ann Oncol 2016; 27 (3): 390–397. doi: org/10.1093/annonc/mdv616 

*Musa M, Radman M, Krisko A. Decreasing translation error rate in Escherichia coli increases protein function. BMC Biotechnol 2016; 16:28. doi: 10.1186/s12896-016-0259-8

*Nikolić A , Perić M , Ladouce R. Death by UVC Light Correlates with Protein Damage in Isogenic Human Tumor Cells: Primary Tumor SW480 versus its Metastasis SW620. J Proteomics Computational Biol 2016; 2(1):1-12

*Perić M, Bou Dib P, Dennerlein S, et al. Crosstalk between cellular compartments protects against proteotoxicity and extends lifespan. Sci Rep 2016; 6: 28751. doi: 10.1038/srep28751

*Sebbagh S, Roux J, Dreyer C, et al. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers. Acta Oncol 2016; 55(9-10):1168-1174. doi: 10.1080/0284186X.2016.1191670


*Cauchy F, Mebarki M, Albuquerque M, et al. Anti-angiogenic effect of metformin in human liver carcinogenesis related to metabolic syndrome. Gut 2015;64(9):1498-500. doi: 10.1136/gutjnl-2015-310069

*Conconi A1, Lobetti-Bodoni C2, Montoto S, et al. Life expectancy of young adults with follicular lymphoma. Ann Oncol 2015; 26(11):2317-22. doi: 10.1093/annonc/mdv376

*Crescenzo R, Abate F, Lasorsa E et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 2015; 27(4):516-32. doi: 10.1016/j.ccell.2015.03.006

*Eleveld TF, Oldridge DA2, Bernard V, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet 2015;47(8):864-71. doi: 10.1038/ng.3333

*Malouf GG, Tahara T, Paradis V, et al. Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features. Epigenetics. 2015; 10(9): 872–881. doi: 10.1080/15592294.2015.1076955

*Neuzillet C, Tijeras-Raballand A, Cohen R, et al. Targeting the TGFβ pathway for cancer therapy.  Pharmacol Ther. 2015; 147:22-31. doi: 10.1016/j.pharmthera.2014.11.001

*Neuzillet C, Couvelard A, Tijeras-Raballand A et al. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. Histopathology 2015; 67(5):664-76. doi: 10.1111/his.12691

*Serova M, Tijeras-Raballand A, Dos Santos C, et al. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget. 2015; 6(25):21614-27. doi: 10.18632/oncotarget.4308 


*Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, et al. Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev 2014;40(2):307-19. doi: 10.1016/j.ctrv.2013.07.007

*Bouska A1, McKeithan TW, Deffenbacher KE, et al. Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood 2014; 123(11):1681-90. doi: 10.1182/blood-2013-05-500595

*Collins A, Wojcik S, Frankel W, et al. A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma. Ann Surg Oncol 2014; 21(1):133-8. doi: 10.1245/s10434-013-3240-y

*Ghanem I, Riveiro ME, Paradis V, et al. Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis. Am J Transl Res 2014; 6(4):340-52.

*Malouf GG, Job S, Paradis V, et al. Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature. Hepatology 2014; 59(6):2228-37. doi: 10.1002/hep.27018

*Malouf G, Taube J, Lu Y et al. « Architecture of Epigenetic Reprogramming Following Twist1-Mediated Epithelial-Mesenchymal Transition ». In  Cancer Cell Signaling: Targeting Signaling Pathways Toward Therapeutic Approaches to Cancer. K Ayyanathan (Ed). Oakville, Canada. Apple Academic Press. 2014, p253. ISBN 9781771880671. 

*Neuzillet C, de Gramont A, Tijeras-Raballand A, et al. Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas. Oncotarget 2014; 5(1):78-94. doi: 10.18632/oncotarget.1569

*Zucca E, Stathis A, Bertoni F. The management of nongastric MALT lymphomas. Oncology (Williston Park). 2014;28(1):86-93


*Bertoni F, Li ZM, & Zucca E.  “Where do we stand in the genomics of lymphomas?” In: Pfeffer U. (Ed) Cancer Genomics: Molecular Classification, Prognosis and Response Prediction. Springer-Verlag, 2013. ISBN 978-94-007-5842-1

*Conconi A, Franceschetti S, Lobetti-Bodoni C, et al. Risk factors of central nervous system relapse in mantle cell lymphoma. Leuk Lymphoma 2013; 54(9):1908-14. doi: 10.3109/10428194.2013.767454

*Dings RP, Levine J, Brown SG, et al. Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer. Invest New Drugs 2013;31(5):1142-50. doi: 10.1007/s10637-013-9932-0

*Li ZM, Spagnuolo L, Mensah AA, et al. Gains of CCND3 gene in ocular adnexal MALT lymphomas: an integrated analysis. Br J Haematol 2013; 160 (5): 719-22. doi: 10.1111/bjh.12161

*Malouf GG, Taube JH, Lu Y, Roysarkar T et al. Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition. Genome Biol 2013; 14(12):R144. doi: 10.1186/gb-2013-14-12-r144

*Mian M, Rinaldi A, Mensah AA, et al.  Large genomic aberrations detected by SNP-array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. Ann Oncol 2013; 23: 729-735. doi: 10.1093/annonc/mds646

*Neuzillet C, Hammel P, Tijeras-Raballand A, et al.  Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. Cancer Metastasis Rev 2013 Jun;32(1-2):147-62. doi: 10.1007/s10555-012-9396-2

*Rinaldi A, Mensah AA, Kwee I, et al. Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma. Br J Haematol 2013;163(2):194-204. doi: 10.1111/bjh.12515

*Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013; 121(8): 1403-1412. doi: 10.1182/blood-2012-09-458265

*Serova M, de Gramont A, Tijeras-Raballand A, et al.  Benchmarking effects of mTOR, PI3K, and dual PI3K/Mtor inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib. Cancer Chemother Pharmacol. 2013; 71(5):1297-307. doi: 10.1007/s00280-013-2129-6

*Taube JH1, Malouf GG, Lu E, Sphyris N et al. Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. Sci Rep. 2013;3:2687. doi: 10.1038/srep02687 


*Agnelli L, Mereu E, Pellegrino E, et al. Identification of a three-gene model as a powerful diagnostic tool for the recognition of ALK negative ALCL. Blood 2012; 120(6):1274-81.

*Albert S, Hourseau M, Halimi C, et al.  Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue. Oral Oncol 2012;48(12):1263-71. doi: org/10.1016/j.oraloncology.2012.06.010

*Delbaldo C, Faivre S, Dreyer C et al. Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential. Ther Adv Med Oncol 2012; 4(1):9-18. doi: 10.1177/1758834011428147

*Dings RP, Miller MC, Nesmelova I, et al. Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem 2012;55(11):5121-9. doi: 10.1021/jm300014q

*Li ZM, Rinaldi A, Cavalli A, et al. MYD88 somatic mutations in MALT lymphomas. Br J Haematol 2012; 158(5):662-4. doi: 10.1111/j.1365-2141.2012.09176.x

*Malouf GG, Brugières L, Le Deley MC, et al. Pure and mixed fibrolamellar hepatocellular carcinoma differs in their natural history and prognosis. Cancer. 2012; 15;118(20):4981-90. doi: 10.1002/cncr.27520

*Molinari F, Frattini M. KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem. Expert Rev Mol Diagn 2012;12(2):123-6. doi: 10.1586/erm.11.94

*Raymond E, Dreyer C, Faivre S. Targeting neuroendocrine tumor: mixing standard options with novel therapies. Target Oncol 2012; 7(3):151-2. doi: 10.1007/s11523-012-0231-z

*Raymond E, Ruszniewski P. New treatments of pancreatic neuroendocrine tumors: why using them? How to use them? Target Oncol 2012; 7(2):91-2. doi: 10.1007/s11523-012-0222-0.

*Raymond E, Hammel P, Dreyer C, et al. Sunitinib in pancreatic neuroendocrine tumors. Target Oncol 2012; 7(2):117-25. doi: 10.1007/s11523-012-0220-2

*Rossi R, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: Activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med 2012: 27;209(9):1537-51. doi: 10.1084/jem.20120904


*Lambiv WL1, Vassallo I, Delorenzi M et al. The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro Oncol 2011; 13(7):736-47. doi: 10.1093/neuonc/nor036

Burgess BL, Rao NP, Eskin A, et al. Characterization of three cell lines derived from fine needle biopsy of choroidal melanoma with metastatic outcome. Mol Vis. 2011 Feb 25;17:607-15

McCannel TA, Burgess BL, Nelson SF, et al. Genomic identification of significant targets in ciliochoroidal melanoma. Invest Ophthalmol Vis Sci. 2011 May 9;52(6):3018-22. doi: 10.1167/iovs.10-5864 


*O’Toole D, Couvelard A, Rebours V, et al. Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. Endocr Relat Cancer 2010; 17(4):847-56. doi: 10.1677/ERC-09-0204

*Yachida S, Jones S, Bozic I et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010; 467(7319):1114-7. doi: 10.1038/nature09515


*Chandarlapaty S, Sawai A, Ye Q, et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res. 2008; 14(1):240-8. doi: 10.1158/1078-0432.CCR-07-1667

*Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related « self-renewal » signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008;26(18):3015-24. doi: 10.1200/JCO.2007.15.7164 


*Chinot OL, Barrié M, Fuentes S, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 2007;25(12):1470-5. doi: 10.1200/JCO.2006.07.4807

*Cho D, Signoretti S, Dabora S, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2007; 5(6):379-85. 


*Colin C, Baeza N, Bartoli C, et al. Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization. Oncogene 2006; 25(19):2818-26. doi: org/10.1038/sj.onc.1209305


*Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003. doi: 10.1056/NEJMoa043331